Funding

WellDoc Raises $22M in Series B

88 Views

What does WellDoc do?

WellDoc, is a digital health technology company which develops solutions for transforming the management of chronic disease.  The company is developing the next gen tech solutions for supporting chronic diseases management. The company’s aim is improving the lives of people who are suffering from chronic diseases. It fulfils its mission by integrating clinical, behavioural and motivational applications with everyday technologies, such as the cell phone and internet, for engaging patients and healthcare providers in ways which dramatically improve outcomes and significantly reducing healthcare costs.

How much WellDoc was funded?

WellDoc raised $22M in Series B on December 17, 2015 from Hudson River Capital Partners,  Excel Venture Management, Alexandria Venture Investment, Adage Capital Management, Samsung Ventures and Merck Global Health Innovation Fund.

Previous funding

  • $196.97k in undisclosed on March 20, 2009
  • $1M in undisclosed round on December 20, 2013
  • $20M in Series A on January 10, 2014 from Merck Global Health Innovation Fund and Windham Venture Partners
  • $4.23M in undisclosed round on February 23, 2015
  • $225k on July 31, 2015

 What is next for WellDoc?

WellDoc has completed the initial closing of its Series B round and is expecting the final closing of the round by the end of coming January. As a part of the latest funding round, Excel Venture Management and Samsung Ventures will each provide a new member to the company’s board of directors. The company plans to use the funding for continuing the commercialization and accelerating adoption of BlueStar, the company’s flagship product. This is a first in class patient centres product which is cleared by the U.S. FDA for the adults with Type II Diabetes and their doctors.

More about WellDoc

WellDoc was founded on March 1, 2005 by Ryan Sysko, Yves Nordmann and Suzanne Sysko Clough. It has its headquarters in Baltimore, MD. The company develops mobile solutions for driving behavioral and clinical changes in chronic diseases.

 

 

Top of Form

Bottom of Form

 

 

 

 

Related Posts